{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T06:48:54Z","timestamp":1792910934011,"version":"4.5.0"},"reference-count":40,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014756","name":"Hexal AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022606","name":"Almirall","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Innovation Fund of the Federal Joint Committee","award":["01VSF17022"],"award-info":[{"award-number":["01VSF17022"]}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Relapse risk after delivery is increased in women with active multiple sclerosis (MS), the best strategy to reduce it is unknown. We aimed to assess the association of four different postpartum strategies with relapses during the first 6 months post partum.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This cohort study includes data prospectively collected through structured telephone interviews from the German Multiple Sclerosis and Pregnancy Registry. Pregnancies with active MS (fingolimod or natalizumab treatment OR relapse within 1\u2009year before pregnancy) and postpartum follow-up of \u22656 months were included. We compared four strategies: (1) intention to breastfeed exclusively without disease-modifying therapy (DMT) (exclusive breast feeding \u22652 months or switching to non-exclusive\/weaning within 2 weeks after a relapse during the first 2 months), (2) early treatment with natalizumab\/fingolimod and (3) other DMT initiated within 6 weeks post partum before a relapse. If women did not or only partially breastfed, or started DMT\u22646 weeks after delivery after a relapse or later, we assumed (4) no-DMT-no-exclusive- breastfeeding-strategy. Main outcome was time to postpartum MS relapses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In 867\u2009women with 911 pregnancies, most (n=416) intended to breastfeed exclusively or had no-DMT-no-exclusive-breastfeeding-strategy (n=290); fewer started fingolimod (n=38), natalizumab (n=74) or another DMT (n=93) early. Recurrent time-to-event analysis showed a statistically significant reduction in relapse hazard only with the natalizumab\/fingolimod-strategy as of months 3\u20134 post partum compared with intention-to-breastfeed-exclusively-strategy. The very early relapse risk was highest in no-DMT-no-exclusive-breastfeeding-strategy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In active MS, an early postpartum treatment strategy should be determined well before delivery. Natalizumab\/fingolimod-strategy reduced postpartum relapse hazard from month 3, but none diminished the early postpartum relapse hazard.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2023-331525","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T17:21:11Z","timestamp":1691083271000},"page":"151-157","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Early postpartum treatment strategies and early postpartum relapses in women with active multiple sclerosis"],"prefix":"10.1136","volume":"95","author":[{"given":"Sabrina","family":"Haben","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea I","family":"Ciplea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Tokic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Timmesfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette Magdalene","family":"Langer-Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4467-9011","authenticated-orcid":false,"given":"Kerstin","family":"Hellwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,8,3]]},"reference":[{"key":"2024011107550741000_95.2.151.1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/1352458518816614","article-title":"Pregnancy and multiple sclerosis in the DMT era: a cohort study in Western Austria","volume":"26","author":"Bsteh","year":"2020","journal-title":"Mult Scler"},{"key":"2024011107550741000_95.2.151.2","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000012084"},{"key":"2024011107550741000_95.2.151.3","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2015.1806","article-title":"Exclusive breastfeeding and the effect on postpartum multiple sclerosis relapses","volume":"72","author":"Hellwig","year":"2015","journal-title":"JAMA Neurol"},{"key":"2024011107550741000_95.2.151.4","doi-asserted-by":"crossref","first-page":"e1939","DOI":"10.1212\/WNL.0000000000009374","article-title":"Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort","volume":"94","author":"Langer-Gould","year":"2020","journal-title":"Neurology"},{"key":"2024011107550741000_95.2.151.5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/jamaneurol.2019.4173","article-title":"Association between breastfeeding and postpartum multiple sclerosis relapses: a systematic review and meta-analysis","volume":"77","author":"Krysko","year":"2020","journal-title":"JAMA Neurol"},{"key":"2024011107550741000_95.2.151.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6553-z"},{"key":"2024011107550741000_95.2.151.7","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.132"},{"key":"2024011107550741000_95.2.151.8","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.281"},{"key":"2024011107550741000_95.2.151.9","doi-asserted-by":"crossref","unstructured":"Simpson A , Mowry EM , Newsome SD . Early aggressive treatment approaches for multiple sclerosis. Curr Treat Options Neurol 2021;23:19. doi:10.1007\/s11940-021-00677-1","DOI":"10.1007\/s11940-021-00677-1"},{"key":"2024011107550741000_95.2.151.10","doi-asserted-by":"crossref","unstructured":"Hellwig K , Tokic M , Thiel S , et al . Multiple sclerosis disease activity and disability following discontinuation of natalizumab for pregnancy. JAMA Netw Open 2022;5:e2144750. doi:10.1001\/jamanetworkopen.2021.44750","DOI":"10.1001\/jamanetworkopen.2021.44750"},{"key":"2024011107550741000_95.2.151.11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7812\/TPP\/13-090","article-title":"Immunomodulatory agents and risk of postpartum multiple sclerosis relapses","volume":"18","author":"Beaber","year":"2014","journal-title":"Perm J"},{"key":"2024011107550741000_95.2.151.12","doi-asserted-by":"crossref","unstructured":"Thiel S , Ciplea AI , Gold R , et al . The German multiple sclerosis and pregnancy registry: rationale, objective, design, and first results. Ther Adv Neurol Disord 2021;14:17562864211054956. doi:10.1177\/17562864211054956","DOI":"10.1177\/17562864211054956"},{"key":"2024011107550741000_95.2.151.13","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000005065"},{"key":"2024011107550741000_95.2.151.14","doi-asserted-by":"crossref","unstructured":"Prosperini L , Kinkel RP , Miravalle AA , et al . Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord 2019;12:1756286419837809. doi:10.1177\/1756286419837809","DOI":"10.1177\/1756286419837809"},{"key":"2024011107550741000_95.2.151.15","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513507816"},{"key":"2024011107550741000_95.2.151.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"2024011107550741000_95.2.151.17","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.64"},{"key":"2024011107550741000_95.2.151.18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.msard.2017.07.002","article-title":"Pregnancy in multiple sclerosis: a Portuguese cohort study","volume":"17","author":"Jesus-Ribeiro","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"2024011107550741000_95.2.151.19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.7224\/1537-2073-4.4.183","article-title":"Influence of infant feeding method on postpartum relapse of mothers with MS","volume":"4","author":"Gulick","year":"2002","journal-title":"Int J MS Care"},{"key":"2024011107550741000_95.2.151.20","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.304"},{"key":"2024011107550741000_95.2.151.21","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514554056"},{"key":"2024011107550741000_95.2.151.22","doi-asserted-by":"crossref","unstructured":"Portaccio E , Amato MP . Author response: pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: fetal risks. Neurology 2018;91:851. doi:10.1212\/WNL.0000000000006430","DOI":"10.1212\/WNL.0000000000006430"},{"key":"2024011107550741000_95.2.151.23","doi-asserted-by":"crossref","unstructured":"Razaz N , Piehl F , Frisell T , et al . Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab. Neurol Neuroimmunol Neuroinflamm 2020;7:e903. doi:10.1212\/NXI.0000000000000903","DOI":"10.1212\/NXI.0000000000000903"},{"key":"2024011107550741000_95.2.151.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01024-7"},{"key":"2024011107550741000_95.2.151.25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-6773.2005.00453.x"},{"key":"2024011107550741000_95.2.151.26","doi-asserted-by":"publisher","DOI":"10.1111\/apa.13102"},{"key":"2024011107550741000_95.2.151.27","unstructured":"EMA . Betaferon (interferon beta 1B) EPAR summary of product characteristics. 2021. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/betaferon-epar-product-information_en.pdf"},{"key":"2024011107550741000_95.2.151.28","unstructured":"Copaxone 40 mg\/ml solution for injection in pre-filled syringe electroninic medicines compendium (emc). 2022. Available: https:\/\/www.medicines.org.uk\/emc\/product\/7046\/smpc#gref"},{"key":"2024011107550741000_95.2.151.29","unstructured":"EMA . Kesimpta\u00ae (Ofatumumab) - EPAR summary of product Charcteristics. 2021. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kesimpta-epar-product-information_en.pdf"},{"key":"2024011107550741000_95.2.151.30","doi-asserted-by":"crossref","unstructured":"Krysko KM , LaHue SC , Anderson A , et al . Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions. Neurol Neuroimmunol Neuroinflamm 2020;7:e637. doi:10.1212\/NXI.0000000000000637","DOI":"10.1212\/NXI.0000000000000637"},{"key":"2024011107550741000_95.2.151.31","unstructured":"Anderson A , Jacobs D , LaHue SC , et al . Ocrelizumab in postpartum women with multiple sclerosis: low transfer into breast milk and reassuring infant development in a multicenter cohort. Actrims 2022 Forum; Florida, U.S.2022"},{"key":"2024011107550741000_95.2.151.32","doi-asserted-by":"crossref","unstructured":"Proschmann U , Haase R , Inojosa H , et al . Drug and neurofilament levels in serum and breastmilk of women with multiple sclerosis exposed to natalizumab during pregnancy and lactation. Front Immunol 2021;12:715195. doi:10.3389\/fimmu.2021.715195","DOI":"10.3389\/fimmu.2021.715195"},{"key":"2024011107550741000_95.2.151.33","doi-asserted-by":"crossref","unstructured":"Ciplea AI , Langer-Gould A , de Vries A , et al . Monoclonal antibody treatment during pregnancy and\/or lactation in women with MS or neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm 2020;7:e723. doi:10.1212\/NXI.0000000000000723","DOI":"10.1212\/NXI.0000000000000723"},{"key":"2024011107550741000_95.2.151.34","doi-asserted-by":"crossref","unstructured":"Krysko KM , Graves JS , Dobson R , et al . Sex effects across the lifespan in women with multiple sclerosis. Ther Adv Neurol Disord 2020;13:1756286420936166. doi:10.1177\/1756286420936166","DOI":"10.1177\/1756286420936166"},{"key":"2024011107550741000_95.2.151.35","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1177\/1352458520912173","article-title":"Cladribine transfer into human milk: a case report","volume":"27","author":"Datta","year":"2021","journal-title":"Mult Scler"},{"key":"2024011107550741000_95.2.151.36","doi-asserted-by":"crossref","unstructured":"Ciplea AI , Datta P , Rewers-Felkins K , et al . Dimethyl fumarate transfer into human milk. Ther Adv Neurol Disord 2020;13:1756286420968414. doi:10.1177\/1756286420968414","DOI":"10.1177\/1756286420968414"},{"key":"2024011107550741000_95.2.151.37","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1001\/jamaneurol.2013.4290","article-title":"Early child development and exposure to antiepileptic drugs prenatally and through breastfeeding: a prospective cohort study on children of women with epilepsy","volume":"70","author":"Veiby","year":"2013","journal-title":"JAMA Neurol"},{"key":"2024011107550741000_95.2.151.38","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/jamapediatrics.2014.118","article-title":"Breastfeeding in children of women taking antiepileptic drugs: cognitive outcomes at age 6 years","volume":"168","author":"Meador","year":"2014","journal-title":"JAMA Pediatr"},{"key":"2024011107550741000_95.2.151.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2015.02.013"},{"key":"2024011107550741000_95.2.151.40","doi-asserted-by":"crossref","unstructured":"Costanza M , Pedotti R . Prolactin: friend or foe in central nervous system autoimmune inflammation? Int J Mol Sci 2016;17:2026. doi:10.3390\/ijms17122026","DOI":"10.3390\/ijms17122026"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2023-331525","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T15:56:16Z","timestamp":1704988576000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2023-331525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1,11]]},"published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1136\/jnnp-2023-331525"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2023-331525","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,3]]}}}